About this Research Topic
CD4+Th2 cell is known to be involved in triggering immune overactivation and pathogenesis of skin disorders. This Research Topic will focus on the importance of allergic Th2-mediated responses and cytokines/chemokines (e.g., IL-4, IL-13, IL-5, IL-31, TARC, PARC) in the development of the skin disorders, including atopic dermatitis (AD), bullous pemphigoid (BP), urticaria, drug hypersensitivity syndrome with systemic symptoms (DRESS), etc.
Recently, novel anti-IL4 biologic agents or targeted JAK inhibitors (JAKi) have been shown to effectively treat a variety of skin disorders. As such this this Research Topic welcomes manuscripts about novel targeted therapy, updating the treatment outcome or identifying biomarkers for Th2-associated skin disorders.
The goal of this research topic is to not only provide a forum to advance research on the contribution of Th2-mediated skin inflammation but also explore important targets/biomarkers for treatment or monitoring, to improve the therapeutic effectiveness for Th2-associated skin disorders.
This Research Topic welcomes manuscripts on:
1) Immune mechanisms of Th2-associated skin disorders.
2) Immunopathology of Th2-mediated cytokines and chemokines (such as L-4, IL-13, IL-5, IL-31, TARC, PARC, etc.) to skin disorders.
3) Novel therapeutic strategies or meta-analysis study on treatment outcomes for Th2-associated skin disorders.
4) Pharmacogenetics or pharmacogenomics for severe cutaneous adverse drug reactions, especially in drug hypersensitivity syndrome with systemic symptoms (DRESS).
5) Personalized immunotherapies of Th2-associated skin disorders.
6) Biomarkers for monitoring or improving the therapeutic effectiveness for Th2-associated skin disorders.
7) Big data analysis for Th2-associated skin disorders.
8) Case report or case series study of novel targeted therapy for Th2-associated skin disorders.
Recently, novel anti-IL4 biologic agents or targeted JAK inhibitors (JAKi) have been shown to effectively treat a variety of skin disorders. As such this this Research Topic welcomes manuscripts about novel targeted therapy, updating the treatment outcome or identifying biomarkers for Th2-associated skin disorders.
The goal of this research topic is to not only provide a forum to advance research on the contribution of Th2-mediated skin inflammation but also explore important targets/biomarkers for treatment or monitoring, to improve the therapeutic effectiveness for Th2-associated skin disorders.
This Research Topic welcomes manuscripts on:
1) Immune mechanisms of Th2-associated skin disorders.
2) Immunopathology of Th2-mediated cytokines and chemokines (such as L-4, IL-13, IL-5, IL-31, TARC, PARC, etc.) to skin disorders.
3) Novel therapeutic strategies or meta-analysis study on treatment outcomes for Th2-associated skin disorders.
4) Pharmacogenetics or pharmacogenomics for severe cutaneous adverse drug reactions, especially in drug hypersensitivity syndrome with systemic symptoms (DRESS).
5) Personalized immunotherapies of Th2-associated skin disorders.
6) Biomarkers for monitoring or improving the therapeutic effectiveness for Th2-associated skin disorders.
7) Big data analysis for Th2-associated skin disorders.
8) Case report or case series study of novel targeted therapy for Th2-associated skin disorders.
Keywords: Atopic dermatitis (AD), Bullous pemphigoid (BP), CD4+Th2 cell, drug hypersensitivity syndrome with systemic symptoms (DRESS), pharmacogenetics, targeted therapy, urticaria
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
